PMID: 2493715Jan 1, 1989Paper

Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure

Advances in Nephrology From the Necker Hospital
T DrüekeS Delons

Abstract

Administration of recombinant erythropoietin constitutes a revolution in treatment of the anemia of chronic dialysis patients. Such treatment has been anxiously awaited. Its realization has been possible thanks to the spectacular progress allowed by the newly developed techniques of recombinant genetics. Correction of this type of anemia can be obtained rapidly and permanently if treatment is continued without interruption. It is followed by a remarkable transformation of the patient's physical and psychic status. The occurrence of certain side effects (e.g., elevation of blood pressure and an increased tendency toward vascular thrombosis), however, requires increased awareness in the follow-up of patients at risk and adaptation of erythropoietin administration to individual needs.

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Anales de medicina interna : organo oficial de la Sociedad Española de Medicina Interna
A ZapateroJ Ruiz Galiana
American Journal of Translational Research
Belisario A ArangoStefan Glück
Annals of the Academy of Medicine, Singapore
D C H Harris, G K Rangan
© 2022 Meta ULC. All rights reserved